Patrick Y. Wen

Director, Center For Neuro-Oncology
Dana-Farber Cancer Institute

Dr Patrick Y Wen is Professor of Neurology at Harvard Medical School and Director of the Center For Neuro-Oncology at Dana-Farber/Brigham and Womens’ Cancer Center. He is currently the President of the Society For Neuro-Oncology. He was formerly the Editor-In-Chief of Neuro-Oncology and currently SNO Executive Editor of Neuro-Oncology. He is also a steering committee member of the Response Assessment in Neuro-Oncology (RANO) Working Group. His research interest is novel therapeutics for brain tumors, as well as novel clinical trial designs and response assessment and endpoints in clinical trials.

Disclosure: Nothing to disclose

Presentation(s):

• Best practices in the management of cerebral edema in primary and metastatic disease

  Thursday, November 21
  1:40 PM – 2:05 PM

• Presidential Address-SNO Business

  Friday, November 22
  10:50 AM – 11:20 AM

• ACTR-58 - Baseline requirements for novel agents being considered for brain cancer efficacy trials: Report of an ABTC Workshop

  Friday, November 22
  1:30 PM – 1:40 PM

• ACTR-66 - A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent IDH1 mutant, low-grade glioma: Updated results

  Friday, November 22
  2:50 PM – 2:55 PM

• ACTR-30 - Updated efficacy and safety of dabrafenib plus trametinib in patients with recurrent/refractory BRAF V600E–mutated high-grade glioma (HGG) and low-grade glioma (LGG)

  Friday, November 22
  3:25 PM – 3:35 PM

• DRES-08 - Clinical Significance of Hypermutation in Gliomas

  Friday, November 22
  3:25 PM – 3:35 PM

• RBTT-08 - A randomized phase 2 open label study of nivolumab plus standard dose bevacizumab versus nivolumab plus low dose bevacizumab in recurrent glioblastoma (GBM)

  Friday, November 22
  7:30 PM – 9:30 PM

• ACTR-34 - Single agent ONC201 in previously-treated, progressive adult H3 K27M-mutant glioma

  Friday, November 22
  7:30 PM – 9:30 PM

• ACTR-64 - Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 in GBM patients with unmethylated O₆-methylguanine-methyltransferase (MGMT) promoter status

  Friday, November 22
  7:30 PM – 9:30 PM

• NIMG-54 - Diffusion MRI phenotypes predict overall survival benefit from bevacizumab in recurrent glioblastoma with a large tumor burden: Evidence from clinical practice and a multicenter phase 3 trial

  Friday, November 22
  7:30 PM – 9:30 PM

• ATIM-26 - Interim results of the extension phase of a Phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)

  Friday, November 22
  7:30 PM – 9:30 PM

• Victor Levin Award Lecture

  Saturday, November 23
  10:17 AM – 10:47 AM

• Introduction

  Saturday, November 23
  3:15 PM – 3:20 PM

• NIMG-34 - Multi-parametric MR-PET imaging predicts pharmacokinetics and clinical response to GDC-0084 in human recurrent high-grade glioma

  Saturday, November 23
  3:15 PM – 3:25 PM

• PDCT-12 - Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma

  Saturday, November 23
  3:45 PM – 3:55 PM

• Discussion and Wrap-Up - RANO: Where Next?

  Saturday, November 23
  4:50 PM – 5:00 PM

• ACTR-43 - Genomic analysis of responders of phase II trial of temozolomide and TRC-102 (base excision repair inhibitor) in bevacizumab-naïve glioblastoma at first recurrence

  Saturday, November 23
  5:00 PM – 7:00 PM

• NIMG-47 - Volumetric Analysis of Phase 2 and 3 Trials in Recurrent Glioblastoma Treated with VB-111 with or without Bevacizumab or Bevacizumab Monotherapy

  Saturday, November 23
  5:00 PM – 7:00 PM

• ATIM-09 - Clinical trial in progress: A study of neoadjuvant and adjuvant VB-111 for treatment of recurrent GBM

  Saturday, November 23
  5:00 PM – 7:00 PM

• ACTR-33 - Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study

  Saturday, November 23
  5:00 PM – 7:00 PM

• INNV-33 - Barriers to Accrual and Enrollment in Brain Tumor Trials

  Saturday, November 23
  5:00 PM – 7:00 PM

• ACTR-39 - Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with newly diagnosed or recurrent/refractory (R/R) glioblastoma (GBM); phase 1b/2 study update

  Saturday, November 23
  5:00 PM – 7:00 PM

• IMMU-18 - Immunogenomic Responder Phenotype from a Phase I Trial of Anti-LAG3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM

  Sunday, November 24
  9:55 AM – 10:00 AM

• ATIM-40 - Circulating Myeloid-Derived Suppressor Cells Predict Favorable Response to Immune Checkpoint Therapy in a Randomized Trial of Nivolumab and Bevacizumab in Recurrent GBM

  Sunday, November 24
  10:00 AM – 10:05 AM